Target intelligence / Profile preview

Histone deacetylase 1, 2, 3, and 11 (HDAC1, HDAC2, HDAC3, HDAC11)

Target
HDAC1, HDAC2, HDAC3, HDAC11
Molecular classification
Enzyme, Histone deacetylase, Epigenetic regulator, Zinc-dependent hydrolase, Class I HDACs, Class IV HDAC
01

Overview

Histone deacetylases 1, 2, 3, and 11 are nuclear enzymes in the HDAC family that catalyze the removal of acetyl groups from lysine residues, playing a central role in the repression of gene transcription through chromatin condensation. HDAC1, 2, and 3 share high sequence homology and are found primarily in multi-protein complexes regulating gene silencing, cell cycle progression, and cellular differentiation. HDAC11, the only member of class IV, has functions distinct from other classes and has been implicated in immune regulation and mRNA splicing. Dysregulation of these enzymes is associated with oncogenesis and other disease states; thus, their inhibition is a key focus in epigenetic therapy development.

Other names
HDACsRPD3-like proteins (HDAC1/2/3)Class I and Class IV HDACs
02

Mechanism of action

Inhibition of histone deacetylation, leading to increased acetylation of histones and relaxation of chromatin structure, facilitating gene expression. Modulation of non-histone protein acetylation affecting stability, localization, and function of transcription factors and other cellular proteins.

03

Biological functions

Chromatin remodelingTranscriptional repressionRegulation of gene expressionCell cycle controlCell proliferation and differentiationApoptosisDNA repairImmune responseMetabolic pathways
04

Disease associations

CancerNeurological and neurodegenerative diseasesInflammatory diseasesCardiovascular diseasesInfectious diseases
05

Safety considerations

Hematologic toxicity (thrombocytopenia, neutropenia)Gastrointestinal toxicity (nausea, vomiting, diarrhea)Cardiac toxicity (QT prolongation, arrhythmia)FatigueRisk of infection due to immunosuppressionTarget selectivity/isoform selectivity remains a therapeutic challenge for minimizing off-target effects
06

Interacting drugs

Vorinostat (SAHA)

7 more in the full profile.

07

Biomarkers

Levels of histone acetylation (e.g., H3K9ac, H3K18ac, H4K16ac)Specific HDAC isoform expression in tissues or tumorsResponse genes (e.g., p21, associated with cell cycle arrest)In some settings, promoter methylation status or acetylation marks can be used as efficacy readouts

Beyond the preview

Go deeper on Histone deacetylase 1, 2, 3, and 11 (HDAC1, HDAC2, HDAC3, HDAC11).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histone deacetylase 1, 2, 3, and 11 (HDAC1, HDAC2, HDAC3, HDAC11).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call